Zacks Investment Research
10 Aug 2026, 18:06 UTC · 15h ago
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
10 Aug 2026, 18:06 UTC · 15h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ANI Pharmaceuticals lowered its full-year outlook for Cortrophin Gel. — Lowering guidance for a core product typically triggers negative sentiment and price depreciation, as seen in the 5% share drop.
-0.60ANI Pharmaceuticals reported Q2 2026 adjusted EPS of $2.21 and revenue of $266 million, beating Zacks Consensus Estimates. — Positive earnings and revenue surprises generally support a bullish case for a stock's valuation.
+0.40Iluvien revenues declined 16% year-over-year to $18.7 million, missing the Zacks Consensus Estimate. — Revenue declines and misses in specific product lines indicate operational headwinds or shipment timing issues.
-0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Cortrophin Gel revenues grew 43.5% year-over-year to $117.1 million, though this missed analyst estimates. — Strong growth is offset by the failure to meet market expectations for a key revenue driver.
Which stocks this story touches
Despite beating overall earnings and revenue estimates, the company lowered its full-year outlook for Cortrophin and experienced a share price drop.
Mentioned as a licensing partner contributing to ANI Pharmaceuticals' royalty revenues.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Benzinga
3h ago
